A Phase 1 study of CBX-250 in AML, MDS, and CMML

Study Description

A Study of an Investigational Drug (CBX-250) in Patients with Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Study Details

Registry ID:

NCT06994676

Conditions:

High-risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (CMML), AML - Acute Myeloid Leukemia, Chronic Myeloid Leukemia

Phase:

Phase 1

Target Enrollment:

72 participants

Start Date:

July 16, 2025

Age Range:

12–999 years

Healthy Volunteers:

No

Study Locations (11 sites)

• Dana Farber Cancer Institute
  Boston, MassachusettsUnited States, United States
• Memorial Sloan Kettering Cancer Center
  New York, New YorkUnited States, United States
• Thomas Jefferson University Hospital
  Philadelphia, PennsylvaniaUnited States, United States
• Moffitt Cancer Center
  Tampa, FloridaUnited States, United States
• Sarah Cannon Cancer Institute
  Nashville, TennesseeUnited States, United States
• Vanderbilt University Medical Center
  Nashville, TennesseeUnited States, United States
• Northwestern Medicine
  Chicago, IllinoisUnited States, United States
• Washington University in St. Louis
  St Louis, MissouriUnited States, United States
• MD Anderson Cancer Center
  Houston, TexasUnited States, United States
• City of Hope
  Duarte, CaliforniaUnited States, United States
• Stanford Medical Center
  Palo Alto, CaliforniaUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →